mm-093
Recombinant proteinexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2005 (NCT00105976)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Alpha-fetoproteinSupplementation
AFP supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- mm-093
- mm-093
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00444743 | Phase 2 | Feb 1, 2007 | Harvard University, Merrimack Pharmaceuticals |
| NCT00458146 | Phase 2 | Feb 1, 2007 | Merrimack Pharmaceuticals |
| NCT00147329 | Phase 2 | Sep 1, 2005 | Merrimack Pharmaceuticals |
| NCT00105976 | Phase 2 | Feb 1, 2005 | Merrimack Pharmaceuticals |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merrimack Pharmaceuticals | For profit | 4 | 4 | 1 | 2005 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2007 |
2 organizations
Page 1 / 1